Interestingly, treatment with bosentan significantly decreased ET-1 in SSc patients with PAH to levels comparable to those in patients without, indicating that the levels of this peptide could reflect PAH presence as well as the severity and the response to bosentan therapy [73]. This evidence concerns the gene EDN1 and systemic sclerosis.